Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5330736 | 0.85 | ALDH1A1 (0.64) | POLBKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL17331343 | 0.84 | NAMPT (0.55) | KMT2AMEN1ALDH1A1MAPTSNCA | |
| SCHEMBL894613 | 0.84 | POLB (0.82) | POLBPFKFB3KMT2AMEN1ALDH1A1 | |
| SCHEMBL17331338 | 0.83 | NAMPT (0.54) | KMT2AMEN1ALDH1A1MAPTSNCA | |
| SCHEMBL30926721 | 0.82 | ALDH1A1 (0.72) | KMT2AMEN1ALDH1A1MAPTNAMPT | |
| SCHEMBL22633468 | 0.82 | ALDH1A1 (0.72) | KMT2AMEN1ALDH1A1MAPTNAMPT | |
| SCHEMBL2189203 | 0.82 | KMT2A (0.56) | POLBKMT2AALDH1A1MAPTSNCA | |
| SCHEMBL17331317 | 0.82 | SMN1; SMN2 (0.64) | POLBKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL17331320 | 0.81 | SMN1; SMN2 (0.53) | KMT2AMEN1ALDH1A1MAPTSNCA | |
| SCHEMBL784141 | 0.81 | KEAP1 (0.66) | POLBKMT2AMEN1ALDH1A1SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701627-B2 | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-12-17 | — | — | US | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-4439444-A | HISTAMINE RECEPTOR ANTAGONISTS | SANOFI (FR) | 1984-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | POLB 4497/4885PFKFB3 1138/4885KMT2A 2145/4885 |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | LRRK2, PARK7, SNCA | POLB 2683/4885PFKFB3 3497/4885KMT2A 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.